References for Tables 1 and 2

REFERENCES FOR TABLES 1 AND 2:

AIDS VACCINE CANDIDATES STUDIED BY THE AVEG

Table 1: Preventative AIDS Vaccine Candidates Studies by the AVEG

Table 2: Therapeutic Vaccine Candidates Studied by the AVEG

REFERENCE NUMBER
REFERENCE
AVEG PROTOCOL NUMBER

1
Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med. 1991;114:119-127.
003, 003A, 003B

2
Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, AIDS Vaccine Clinical Trials Network. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses. 1994;10:1713-1723.
003, 003A, 003B

3
Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis. 1993;168:1387-1395.
004, 004A, 004B

4
Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, Fast PE, NIAID AIDS Vaccine Clinical Trials Network. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol. 1994;98:178-184.
004, 004A, 004B

5
Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of ENV 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses. 1996;12:683-693.
005A, 005B, 005C

6
Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, Matthews T. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993;342:69-73.
006

7
Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med. 1996;125:270-279.
007A, 007B, 007C

8
Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twadell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast P (NIAID AIDS Vaccine Clinical Trials Network). Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA. 1994;272:475-480.
009

9
Gorse GJ, McElrath MJ, Matthews TJ, Hsieh RH, Belshe RB, Corey L, Frey SE, Kennedy DJ, Walker MC, Eibl MM, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Modulation of immunologic responses to HIV-1_MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 1998;16:493-506.
013A

10
Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). HIV-1_MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1_MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses. 1999;15:115-132.
013B

11
McElrath MJ. Use of rgp120 with multiple adjuvants: AVEG Protocols 015 and 016. Oral Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.
015, 016, 016A, 016B

12
Kallas EG, Evans TG, Gorse G, McElrath MJ, Mulligan M, Matthews T, McNamara J, Wolff M, Francis D, AIDS Vaccine Evaluation Group. QS21 is superior to alum as an adjuvant with low dose recombinant MN gp120 for immunization of HIV-1 uninfected volunteers: cellular and humoral responses. Poster, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998 [88].
016, 016A, 016B

13
Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). A dose-ranging study of a prototype synthetic HIV-1_MN V3 branched peptide vaccine. J Infect Dis. 1996;173:330-339.
011

14
Keefer MC, Lambert JS, Koff W, Weinhold K, Wolff M, Clements ML, Hosein B, Demeter L, Boyle RW, Dolin R, NIAID AIDS Vaccine Clinical Trials Network. A Phase I study of multivalent HIV-1 peptide vaccine in HIV-1 uninfected subjects. Poster, Annual Meeting, Infectious Diseases Society of America, San Francisco, California, September 16-18, 1995 [403].
017

15
Tellez I, Sabbaj S, Bansal A, Goepfert P, Evans T, Graham B, Ginsberg R, Weiner D, Corey L, Weinhold K, Mulligan M. HIV-specific T-cell responses in seronegative volunteers immunized with an HIV-1 gag-pol DNA vaccine. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000 [656].
031

16
Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, Schwartz DH, Agosti JM, Fernie BF, Stablein DM, Montefiori DC, Lambert JS, Hu SL, Esterlitz JR, Lawrence DN, Koff WC, AIDS Vaccine Clinical Trials Network. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis. 1992;166:244-252.
002, 002A, 002B

17
Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, Corey L, Bolognesi DP, Stablein DM, Esterlitz JR, Hu SL, Smith GE, National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis. 1994;170:782-786.
002, 002A, 002B

18
Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA. 1993;90:1882-1886.
002, 002A, 002B

19
Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G, AIDS Vaccine Evaluation Group. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis. 1998;177:301-309.
010

20
Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Duliege AM, Sinangil F, Paoletti E, NIAID AIDS Vaccine Evaluation Group. Immune responses to human immunodeficiency virus HIV-type 1 induced by canarypox expressing HIV-1_MN gp120, HIV-1_SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis. 1998;177:1230-1246.
012A, 012B

21
Keefer MC, McElrath MJ, Weinhold K, Gorse GJ, Mulligan M, Clements-Mann ML, Graham BS, Stablein D, Evans TG, Matthews T, Montefiori D, NIAID AIDS Vaccine Evaluation Group. A Phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120MN [AVEG 014C]. Poster Presentation, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
014C

22
The AIDS Vaccine Evaluation Group 022 Protocol Team: Corey L, Mulligan M, Goepfert P, Sabbaj S, Clements-Mann ML, Harro C, Schwartz D, Dolin R, Evans T, Keefer M, Belshe R, Gorse G, McElrath J, Graham B, Wright P, Spearman P, Weinhold K, Montefiori D, Greenberg M, Klein M, El Habib R, Excler JL, Duliege AM, Stablein D, Wolff M, Smith C, Grabowsky M, Savarese B, Walker MC. Cellular and humoral immune responses to a canarypox (CP) vaccine containing HIV-1 env, gag-pol in combination with rgp120 (AVEG Protocol 022). 2000;Submitted, J Infect Dis.
022, 022A

23
Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J, NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis.1999;180:290-298.
026

24
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Montefiori D, Bradney A, Weinhold KJ (NIAID AIDS Vaccine Evaluation Group). Induction of immune responses to HIV-1 by canarypox (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. 1998; In press, AIDS.
029

25
McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P, AIDS Vaccine Evaluation Group. A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection. 2000;In press, AIDS Res Hum Retroviruses.
201

26
Schwartz D, Clements ML, Belshe R, Gorse G, Wright P, Graham B. Interim results of rgp160 vaccine trial in HIV+ volunteers. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A28-0668].
101

27
McElrath MJ, Keefer M, Paxton WB, Chernoff D, Sinangil F, Steimer K, Sposto R, Coombs R, Dolin R, Greenberg P, Corey L, NIAID AVEG. A Phase I randomized, blinded, controlled vaccine trial in asymptomatic HIV-infected individuals using ENV 2-3 in MF-59 with or without MTP-PE. Abstract, Annual Meeting, Infectious Diseases Society of America, New Orleans, Louisiana, October 16- 18, 1993 [200].
103, 103A, 103B

28
Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J, AIDS Vaccine Evaluation Group. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus infected pregnant women. 1999;Accepted, J Infect Dis.
104

29
Belshe RB, Stevens C, Gorse G, Buchbinder S, Sridhara R, Self S, Weinhold K, Sheppard H, Duliege AM, Meignier B, McNamara J, Flores J (NIAID AVEG, HIVNET Vaccine Development Groups). Phase II evaluation of a live recombinant canarypox (ALVAC) vector HIV-1 vaccine with or without gp120 subunit HIV-1 vaccine. 13th Meeting, International Society for Sexually Transmitted Diseases Research, Denver, Colorado, July 11-14, 1999 [227].
202

REFERENCE NUMBER	REFERENCE	AVEG PROTOCOL NUMBER
1	Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, NIAID AIDS Vaccine Clinical Trials Network. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med. 1991;114:119-127.	003, 003A, 003B
2	Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, AIDS Vaccine Clinical Trials Network. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses. 1994;10:1713-1723.	003, 003A, 003B
3	Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis. 1993;168:1387-1395.	004, 004A, 004B
4	Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, Fast PE, NIAID AIDS Vaccine Clinical Trials Network. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol. 1994;98:178-184.	004, 004A, 004B
5	Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of ENV 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Hum Retroviruses. 1996;12:683-693.	005A, 005B, 005C
6	Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, Matthews T. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993;342:69-73.	006
7	Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE, NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med. 1996;125:270-279.	007A, 007B, 007C
8	Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twadell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast P (NIAID AIDS Vaccine Clinical Trials Network). Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA. 1994;272:475-480.	009
9	Gorse GJ, McElrath MJ, Matthews TJ, Hsieh RH, Belshe RB, Corey L, Frey SE, Kennedy DJ, Walker MC, Eibl MM, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Modulation of immunologic responses to HIV-1_MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 1998;16:493-506.	013A
10	Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). HIV-1_MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1_MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses. 1999;15:115-132.	013B
11	McElrath MJ. Use of rgp120 with multiple adjuvants: AVEG Protocols 015 and 016. Oral Presentation, 7th Annual Meeting, National Cooperative Vaccine Development Groups for AIDS, Reston, Virginia, November 6-10, 1994.	015, 016, 016A, 016B
12	Kallas EG, Evans TG, Gorse G, McElrath MJ, Mulligan M, Matthews T, McNamara J, Wolff M, Francis D, AIDS Vaccine Evaluation Group. QS21 is superior to alum as an adjuvant with low dose recombinant MN gp120 for immunization of HIV-1 uninfected volunteers: cellular and humoral responses. Poster, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998 [88].	016, 016A, 016B
13	Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE (National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group). A dose-ranging study of a prototype synthetic HIV-1_MN V3 branched peptide vaccine. J Infect Dis. 1996;173:330-339.	011
14	Keefer MC, Lambert JS, Koff W, Weinhold K, Wolff M, Clements ML, Hosein B, Demeter L, Boyle RW, Dolin R, NIAID AIDS Vaccine Clinical Trials Network. A Phase I study of multivalent HIV-1 peptide vaccine in HIV-1 uninfected subjects. Poster, Annual Meeting, Infectious Diseases Society of America, San Francisco, California, September 16-18, 1995 [403].	017
15	Tellez I, Sabbaj S, Bansal A, Goepfert P, Evans T, Graham B, Ginsberg R, Weiner D, Corey L, Weinhold K, Mulligan M. HIV-specific T-cell responses in seronegative volunteers immunized with an HIV-1 gag-pol DNA vaccine. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30-February 2, 2000 [656].	031
16	Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, Schwartz DH, Agosti JM, Fernie BF, Stablein DM, Montefiori DC, Lambert JS, Hu SL, Esterlitz JR, Lawrence DN, Koff WC, AIDS Vaccine Clinical Trials Network. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis. 1992;166:244-252.	002, 002A, 002B
17	Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, Corey L, Bolognesi DP, Stablein DM, Esterlitz JR, Hu SL, Smith GE, National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis. 1994;170:782-786.	002, 002A, 002B
18	Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA. 1993;90:1882-1886.	002, 002A, 002B
19	Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G, AIDS Vaccine Evaluation Group. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis. 1998;177:301-309.	010
20	Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Duliege AM, Sinangil F, Paoletti E, NIAID AIDS Vaccine Evaluation Group. Immune responses to human immunodeficiency virus HIV-type 1 induced by canarypox expressing HIV-1_MN gp120, HIV-1_SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis. 1998;177:1230-1246.	012A, 012B
21	Keefer MC, McElrath MJ, Weinhold K, Gorse GJ, Mulligan M, Clements-Mann ML, Graham BS, Stablein D, Evans TG, Matthews T, Montefiori D, NIAID AIDS Vaccine Evaluation Group. A Phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120MN [AVEG 014C]. Poster Presentation, 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.	014C
22	The AIDS Vaccine Evaluation Group 022 Protocol Team: Corey L, Mulligan M, Goepfert P, Sabbaj S, Clements-Mann ML, Harro C, Schwartz D, Dolin R, Evans T, Keefer M, Belshe R, Gorse G, McElrath J, Graham B, Wright P, Spearman P, Weinhold K, Montefiori D, Greenberg M, Klein M, El Habib R, Excler JL, Duliege AM, Stablein D, Wolff M, Smith C, Grabowsky M, Savarese B, Walker MC. Cellular and humoral immune responses to a canarypox (CP) vaccine containing HIV-1 env, gag-pol in combination with rgp120 (AVEG Protocol 022). 2000;Submitted, J Infect Dis.	022, 022A
23	Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J, NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis.1999;180:290-298.	026
24	Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Montefiori D, Bradney A, Weinhold KJ (NIAID AIDS Vaccine Evaluation Group). Induction of immune responses to HIV-1 by canarypox (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. 1998; In press, AIDS.	029
25	McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P, AIDS Vaccine Evaluation Group. A Phase II study of two HIV-1 envelope vaccines comparing their immunogenicity in populations at risk for acquiring HIV-1 infection. 2000;In press, AIDS Res Hum Retroviruses.	201
26	Schwartz D, Clements ML, Belshe R, Gorse G, Wright P, Graham B. Interim results of rgp160 vaccine trial in HIV+ volunteers. Poster, 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, June 6-11, 1993 [PO-A28-0668].	101
27	McElrath MJ, Keefer M, Paxton WB, Chernoff D, Sinangil F, Steimer K, Sposto R, Coombs R, Dolin R, Greenberg P, Corey L, NIAID AVEG. A Phase I randomized, blinded, controlled vaccine trial in asymptomatic HIV-infected individuals using ENV 2-3 in MF-59 with or without MTP-PE. Abstract, Annual Meeting, Infectious Diseases Society of America, New Orleans, Louisiana, October 16- 18, 1993 [200].	103, 103A, 103B
28	Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J, AIDS Vaccine Evaluation Group. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus infected pregnant women. 1999;Accepted, J Infect Dis.	104
29	Belshe RB, Stevens C, Gorse G, Buchbinder S, Sridhara R, Self S, Weinhold K, Sheppard H, Duliege AM, Meignier B, McNamara J, Flores J (NIAID AVEG, HIVNET Vaccine Development Groups). Phase II evaluation of a live recombinant canarypox (ALVAC) vector HIV-1 vaccine with or without gp120 subunit HIV-1 vaccine. 13th Meeting, International Society for Sexually Transmitted Diseases Research, Denver, Colorado, July 11-14, 1999 [227].	202